NRX Pharmaceuticals Files 8-K with Financials
Ticker: NRXPW · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $8.8 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials, corporate-update
Related Tickers: NRXP
TL;DR
NRXP filed an 8-K on 9/8 for 9/2 events, including financials. Check it out.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on September 8, 2025, reporting on events that occurred on September 2, 2025. The filing includes financial statements and exhibits, and pertains to "Other Events." The company, formerly known as Big Rock Partners Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing provides an update on NRX Pharmaceuticals' corporate activities and financial reporting, which is crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former company name
- September 2, 2025 (date) — Earliest event date
- September 8, 2025 (date) — Filing date
- Delaware (location) — State of incorporation
FAQ
What specific "Other Events" are detailed in this 8-K filing?
The provided text does not specify the 'Other Events'; it only lists 'Other Events' as an item information category.
When was NRX Pharmaceuticals, Inc. previously known as Big Rock Partners Acquisition Corp. and when did the name change occur?
The filing indicates the former company name was Big Rock Partners Acquisition Corp. and the date of the name change was October 12, 2017.
What is the Standard Industrial Classification (SIC) code for NRX Pharmaceuticals, Inc. and what does it represent?
The SIC code is 2834, which corresponds to 'PHARMACEUTICAL PREPARATIONS'.
What is the business and mailing address for NRX Pharmaceuticals, Inc. as listed in the filing?
The business and mailing address for NRX Pharmaceuticals, Inc. is 1201 Orange Street, Suite 600, Wilmington, Delaware 19801.
What is the Commission File Number and EIN for NRX Pharmaceuticals, Inc.?
The Commission File Number is 001-38302 and the EIN is 82-2844431.
Filing Stats: 678 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2025-09-08 16:32:51
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 pershare NRXP The Nasdaq Stock Mark
- $8.8 million — sed an aggregate total of approximately $8.8 million. The Company is filing this current rep
Filing Documents
- nrxp20250908_8k.htm (8-K) — 36KB
- ex_859804.htm (EX-99.1) — 15KB
- nrxlogo.jpg (GRAPHIC) — 2KB
- 0001437749-25-028567.txt ( ) — 208KB
- nrxp-20250902.xsd (EX-101.SCH) — 4KB
- nrxp-20250902_def.xml (EX-101.DEF) — 14KB
- nrxp-20250902_lab.xml (EX-101.LAB) — 18KB
- nrxp-20250902_pre.xml (EX-101.PRE) — 14KB
- nrxp20250908_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On September 2, 2025, NRx Pharmaceuticals, Inc. (the "Company") issued a press release, which in part provides that the Company recently raised an aggregate total of approximately $8.8 million. The Company is filing this current report on Form 8-K to provide ministerial clarification that the aggregate total is comprised of gross proceeds raised through the Company's registered direct common stock offering announced in August 2025, as well as the utilization by the Company of its at-the-market offering program since the current fiscal quarter began on July 1, 2025, each of which include no warrants, repricing adjustments, or other variable rate features. The substantial majority of the $8.8 million in gross proceeds raised through the sale of common stock was placed with experienced biotech investors. A copy of the Press Release is furnished hereto as Exhibit 99.1. The Company will revert to reporting its gross proceeds raised under its ATM in the ordinary course via its Quarterly Reports on Form 10-Q. The information in this Item 8.01 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 8.01 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 2, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: September 8, 2025 By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Interim Chief Executive Officer